Clemens Kratochwil

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7819887/publications.pdf

Version: 2024-02-01

120 papers	14,179 citations	23500 58 h-index	20900 115 g-index
131 all docs	131 docs citations	131 times ranked	6458 citing authors

#	Article	IF	Citations
1	Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	2.8	42
2	Fibroblast Activation Proteinâ€“Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study. Journal of Nuclear Medicine, 2022, 63, 127-133.	2.8	72
3	Positive Multifocal PSMA PET/CT in a Patient With Prostate Cancer and Follicular Lymphoma. Clinical Nuclear Medicine, 2022, 47, e47-e48.	0.7	3
4	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 71-78.	2.0	19
5	Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 871-880.	3.3	80
6	Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. Annals of Nuclear Medicine, 2022, 36, 293-301.	1.2	13
7	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. Journal of Clinical Oncology, 2022, 40, 5043-5043.	0.8	5
8	A Role of Non-FDG Tracers in Lung Cancer?. Seminars in Nuclear Medicine, 2022, 52, 720-733.	2.5	3
9	First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 311-312.	3.3	18
10	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 113-122.	3.3	72
11	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 143-151.	3.3	25
12	FAPI-74 PET/CT Using Either ¹⁸F-AlF or Cold-Kit ⁶⁸Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. Journal of Nuclear Medicine, 2021, 62, 201-207.	2.8	163
13	Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. European Urology, 2021, 79, 343-350.	0.9	128
14	Impact of ⁶⁸Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. Journal of Nuclear Medicine, 2021, 62, 779-786.	2.8	113
15	Diagnostic Accuracy of ¹⁸F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. Journal of Nuclear Medicine, 2021, 62, 208-213.	2.8	77
16	Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2059-2061.	3.3	18
17	Predicting the Risk of Metastases by PSMA-PET/CTâ€”Evaluation of 335 Men with Treatment-NaÃ¯ve Prostate Carcinoma. Cancers, 2021, 13, 1508.	1.7	8
18	[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3011-3013.	3.3	60

#	Article	IF	Citations
19	68Ga-FAPI-PET/CT in patients with various gynecological malignancies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4089-4100.	3.3	91
20	The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4067-4076.	3.3	20
21	Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4377-4385.	3.3	114
22	The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging. PET Clinics, 2021, 16, 341-351.	1.5	18
23	68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas â€“ Imaging analysis and histological validation. Radiotherapy and Oncology, 2021, 160, 192-201.	0.3	40
24	Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 54-63.	3.3	35
25	Ligand engineering for theranostic applications. Current Opinion in Chemical Biology, 2021, 63, 145-151.	2.8	3
26	Two Tumors, One Target. Clinical Nuclear Medicine, 2021, 46, 842-844.	0.7	30
27	Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	5.1	120
28	18F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 26.	1.8	38
29	FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?. Cancers, 2021, 13, 4946.	1.7	67
30	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 729.e7-729.e16.	0.8	34
31	Radioligands Targeting Fibroblast Activation Protein (FAP). Cancers, 2021, 13, 5744.	1.7	30
32	Aktuelle radiopharmazeutische Entwicklungen fÃ¼r die theranostische Anwendung. Radiopraxis, 2021, 14, E83-E98.	0.0	0
33	Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving ²²⁵Ac-PSMA-617 Radioligand Therapy. Journal of Nuclear Medicine, 2020, 61, 62-69.	2.8	128
34	Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Journal of Nuclear Medicine, 2020, 61, 70-79.	2.8	23
35	Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: ⁶⁴Cu- and ²²⁵Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. Journal of Nuclear Medicine, 2020, 61, 563-569.	2.8	176
36	Patients Resistant Against PSMA-Targeting Î±-Radiation Therapy Often Harbor Mutations in DNA Damage-Repairâ€“Associated Genes. Journal of Nuclear Medicine, 2020, 61, 683-688.	2.8	61

#	Article	IF	Citations
37	Lymph Node Involvement in Treatment-NaÃ¯ve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. Journal of Nuclear Medicine, 2020, 61, 46-50.	2.8	26
38	Response Prediction of ¹⁷⁷Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. Journal of Nuclear Medicine, 2020, 61, 689-695.	2.8	39
39	Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2040-2041.	3.3	42
40	Design and Development of ^{99m}Tc-Labeled FAPI Tracers for SPECT Imaging and ¹⁸⁸Re Therapy. Journal of Nuclear Medicine, 2020, 61, 1507-1513.	2.8	110
41	225Ac-PSMA-617 for Therapy of Prostate Cancer. Seminars in Nuclear Medicine, 2020, 50, 133-140.	2.5	78
42	The Role of⁶⁸Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. Journal of Nuclear Medicine, 2020, 61, 1331-1336.	2.8	106
43	FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. European Journal of Radiology, 2020, 127, 109021.	1.2	28
44	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ¯ve metastatic prostate cancer â€“Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	0.8	12
45	Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 5548-5548.	0.8	1
46	Internal Radiation Therapy. Recent Results in Cancer Research, 2020, 216, 881-902.	1.8	3
47	⁶⁸Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. Journal of Nuclear Medicine, 2019, 60, 386-392.	2.8	468
48	Detection Efficacy of ¹⁸F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 362-368.	2.8	238
49	⁶⁸Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. Journal of Nuclear Medicine, 2019, 60, 234-240.	2.8	49
50	Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2761-2769.	1.2	7
51	Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 16.	1.8	134
52	EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2536-2544.	3.3	265
53	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget, 2019, 10, 17-29.	0.8	21
54	FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1754-1755.	3.3	58

#	Article	IF	Citations
55	DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. Mutagenesis, 2019, 34, 239-244.	1.0	12
56	Radionuclide Therapy of Metastatic Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 313-325.	2.5	54
57	Development of Fibroblast Activation Proteinâ€"Targeted Radiotracers with Improved Tumor Retention. Journal of Nuclear Medicine, 2019, 60, 1421-1429.	2.8	281
58	⁶⁸Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. Journal of Nuclear Medicine, 2019, 60, 801-805.	2.8	874
59	Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 139-147.	3.3	72
60	Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing â€œthe leadâ€•into PSMA-targeted alpha therapy?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1081-1091.	3.3	77
61	Dosimetry Estimate and Initial Clinical Experience with ⁹⁰Y-PSMA-617. Journal of Nuclear Medicine, 2019, 60, 806-811.	2.8	27
62	Biochemical Recurrence of Prostate Cancer: Initial Results with [¹⁸F]PSMA-1007 PET/CT. Journal of Nuclear Medicine, 2018, 59, 632-635.	2.8	55
63	Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis. Molecular Imaging and Biology, 2018, 20, 1044-1052.	1.3	3
64	A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. Journal of Nuclear Medicine, 2018, 59, 1423-1429.	2.8	453
65	Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. Journal of Nuclear Medicine, 2018, 59, 1415-1422.	2.8	522
66	Targeted Î±-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. Journal of Nuclear Medicine, 2018, 59, 795-802.	2.8	322
67	Intraindividual Comparison of ^{99m}Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^{99m}Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1373-1379.	2.8	31
68	Role of CT Density in PET/CT-Based Assessment of Lymphoma. Molecular Imaging and Biology, 2018, 20, 641-649.	1.3	6
69	Intraindividual Comparison of ¹⁸F-PSMA-1007 and ¹⁸F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. Journal of Nuclear Medicine, 2018, 59, 1076-1080.	2.8	140
70	[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. Clinical Genitourinary Cancer, 2018, 16, 111-113.	0.9	4
71	Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, 103-105.	0.9	4
72	Simultaneous whole-body 18Fâ€"PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 340-347.	3.3	32

#	Article	IF	Citations
73	Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 31-37.	3.3	107
74	Repeated ¹⁷⁷Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. Journal of Nuclear Medicine, 2018, 59, 459-465.	2.8	68
75	⁶⁸ Ga-DOTA-GGNle-CycMSH _{hex} targets the melanocortin-1 receptor for melanoma imaging. Science Translational Medicine, 2018, 10, .	5.8	30
76	Targeted Alpha Therapy, an Emerging Class of Cancer Agents. JAMA Oncology, 2018, 4, 1765.	3.4	143
77	An Overview of Targeted Alpha Therapy with ²²⁵Actinium and ²¹³Bismuth. Current Radiopharmaceuticals, 2018, 11, 200-208.	0.3	248
78	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2045-2054.	3.3	116
79	Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.. Journal of Clinical Oncology, 2018, 36, 344-344.	0.8	11
80	18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e497-e499.	0.9	47
81	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 950-959.	3.3	69
82	The Future of Radioligand Therapy: Î±, Î², or Both?. Journal of Nuclear Medicine, 2017, 58, 1017-1018.	2.8	53
83	⁶⁸Ga or¹⁸F for Prostate Cancer Imaging?. Journal of Nuclear Medicine, 2017, 58, 687-688.	2.8	105
84	Targeted Î±-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. Journal of Nuclear Medicine, 2017, 58, 1624-1631.	2.8	367
85	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1258-1268.	3.3	425
86	Intraindividual Comparison of ¹⁸F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. Journal of Nuclear Medicine, 2017, 58, 1805-1810.	2.8	91
87	⁶⁸Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. Journal of Nuclear Medicine, 2017, 58, 1943-1948.	2.8	81
88	⁶⁸Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1949-1955.	2.8	27
89	¹⁷⁷Lu-PSMA Radioligand Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1196-1200.	2.8	159
90	German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. Journal of Nuclear Medicine, 2017, 58, 85-90.	2.8	646

#	Article	IF	Citations
91	Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients. Molecular Imaging and Biology, 2017, 19, 315-322.	1.3	30
92	Correlation Between SUV_{max} and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging. Journal of Nuclear Medicine, 2017, 58, 282-287.	2.8	44
93	Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma â€“ Is PSMA-PET-CT a helpful tool in radiation oncology?. Clinical and Translational Radiation Oncology, 2017, 7, 79-82.	0.9	6
94	Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 168-180.	0.4	19
95	Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients. Cancer Imaging, 2017, 17, 30.	1.2	8
96	Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.. Journal of Clinical Oncology, 2017, 35, 155-155.	0.8	2
97	Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC. Diagnostic and Interventional Radiology, 2016, 22, 201-206.	0.7	6
98	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals. Theranostics, 2016, 6, 1085-1095.	4.6	60
99	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 79S-89S.	2.8	200
100	Future trends in prostate cancer theranostics with PSMA ligands. Clinical and Translational Imaging, 2016, 4, 487-489.	1.1	6
101	Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 405-418.	2.5	72
102	²²⁵Ac-PSMA-617 for PSMA-Targeted Î±-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 1941-1944.	2.8	741
103	Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1611-1620.	3.3	143
104	18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1929-1930.	3.3	81
105	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷Lu-Labeled PSMA-617. Journal of Nuclear Medicine, 2016, 57, 1170-1176.	2.8	475
106	68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 34-41.	3.3	194
107	Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 42-51.	3.3	244
108	A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model. Molecular Imaging and Biology, 2016, 18, 243-248.	1.3	4

#	Article	IF	Citations
109	Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to 68Ga-DOTATOC PET. European Journal of Radiology, 2015, 84, 1593-1600.	1.2	21
110	PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 293-298.	2.8	100
111	PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies. Seminars in Nuclear Medicine, 2015, 45, 268-281.	2.5	29
112	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 914-920.	2.8	451
113	[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 987-988.	3.3	155
114	Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro-Oncology, 2015, 17, 312-319.	0.6	64
115	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Journal of Nuclear Medicine, 2015, 56, 1697-1705.	2.8	332
116	The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 197-209.	3.3	866
117	Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro-Oncology, 2014, 16, 434-440.	0.6	120
118	Multimodal Imaging for Early Functional Response Assessment of 90Y-/177Lu-DOTATOC Peptide Receptor Targeted Radiotherapy with DW-MRI and 68Ga-DOTATOC-PET/CT. Molecular Imaging and Biology, 2014, 16, 586-594.	1.3	32
119	Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocrine-Related Cancer, 2011, 18, 595-602.	1.6	79
120	Intraindividual Comparison of Selective Arterial versus Venous 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2010, 16, 2899-2905.	3.2	76